Dutasteride (CAS 164656-23-9) is a high-purity 5α-reductase inhibitor API, renowned for its dual mechanism of action targeting both type I and type II 5α-reductases. With a precise steroid molecular structure, it effectively blocks the conversion of testosterone to dihydrotestosterone (DHT), the more potent active form of androgens.
Produced under strict GMP standards, this API ensures consistent purity (≥99%) and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the treatment of benign prostatic hyperplasia (BPH) and the prevention of prostate cancer, catering to the needs of pharmaceutical manufacturers and research institutions in the urological and endocrinology fields.
Its unique dual inhibition profile provides prolonged efficacy with favorable safety and tolerability, making it a preferred choice for both short-term symptom relief and long-term disease management. Whether for clinical research or large-scale pharmaceutical production, Dutasteride delivers reliable performance for the development of effective treatments for prostate-related disorders.
